762 related articles for article (PubMed ID: 34341985)
1. Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
Basset M; Kimmich CR; Schreck N; Krzykalla J; Dittrich T; Veelken K; Goldschmidt H; Seckinger A; Hose D; Jauch A; Müller-Tidow C; Benner A; Hegenbart U; Schönland SO
Br J Haematol; 2021 Oct; 195(2):230-243. PubMed ID: 34341985
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
Mahmood S; Venner CP; Sachchithanantham S; Lane T; Rannigan L; Foard D; Pinney JH; Gibbs SD; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
Br J Haematol; 2014 Sep; 166(6):842-8. PubMed ID: 24930361
[TBL] [Abstract][Full Text] [Related]
3. A retrospective analysis of treatment outcomes in 45 patients with cardiac light-chain amyloidosis: a single-center experience in Japan.
Fuchida SI; Ide D; Taminishi-Katsuragawa Y; Suga T; Matsui-Maegawa S; Maruyama N; Iwamura Y; Kitamura Y; Okawa Y; Okano A; Hatsuse M; Murakami S; Shimazaki C
Int J Hematol; 2020 Jun; 111(6):803-811. PubMed ID: 32020505
[TBL] [Abstract][Full Text] [Related]
4. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria.
Kimmich CR; Terzer T; Benner A; Dittrich T; Veelken K; Carpinteiro A; Hansen T; Goldschmidt H; Seckinger A; Hose D; Jauch A; Wörner S; Beimler J; Müller-Tidow C; Hegenbart U; Schönland SO
Blood; 2020 Apr; 135(18):1517-1530. PubMed ID: 32107537
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis.
Kastritis E; Gavriatopoulou M; Roussou M; Bagratuni T; Migkou M; Fotiou D; Ziogas DC; Kanellias N; Eleutherakis-Papaiakovou E; Dialoupi I; Ntanasis-Stathopoulos I; Spyropoulou-Vlachou M; Psimenou E; Gakiopoulou H; Marinaki S; Papadopoulou E; Ntalianis A; Terpos E; Dimopoulos MA
Amyloid; 2018 Dec; 25(4):234-241. PubMed ID: 30663408
[TBL] [Abstract][Full Text] [Related]
6. Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.
Palladini G; Milani P; Foli A; Basset M; Russo F; Perlini S; Merlini G
Blood; 2018 Feb; 131(5):525-532. PubMed ID: 29101236
[TBL] [Abstract][Full Text] [Related]
7. Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients.
Milani P; Sharpley F; Schönland SO; Basset M; Mahmood S; Nuvolone M; Kimmich C; Foli A; Sachchithanantham S; Merlini G; Wechalekar A; Palladini G; Hegenbart U
Amyloid; 2020 Dec; 27(4):231-236. PubMed ID: 32449385
[TBL] [Abstract][Full Text] [Related]
8. At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.
Shen KN; Feng J; Huang XF; Zhang CL; Zhang CL; Cao XX; Zhang L; Zhou DB; Li J
Ann Hematol; 2017 Dec; 96(12):2089-2094. PubMed ID: 28956112
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.
Dispenzieri A; Kastritis E; Wechalekar AD; Schönland SO; Kim K; Sanchorawala V; Landau HJ; Kwok F; Suzuki K; Comenzo RL; Berg D; Liu G; Kumar A; Faller DV; Merlini G
Leukemia; 2022 Jan; 36(1):225-235. PubMed ID: 34168284
[TBL] [Abstract][Full Text] [Related]
10. Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone.
Kastritis E; Dialoupi I; Gavriatopoulou M; Roussou M; Kanellias N; Fotiou D; Ntanasis-Stathopoulos I; Papadopoulou E; Ziogas DC; Stamatelopoulos K; Manios E; Ntalianis A; Eleutherakis-Papaiakovou E; Papanikolaou A; Migkou M; Papanota AM; Gakiopoulou H; Psimenou E; Tselegkidi MI; Tsitsilonis O; Kostopoulos I; Terpos E; Dimopoulos MA
Blood Adv; 2019 Oct; 3(20):3002-3009. PubMed ID: 31648323
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
Kastritis E; Roussou M; Gavriatopoulou M; Migkou M; Kalapanida D; Pamboucas C; Kaldara E; Ntalianis A; Psimenou E; Toumanidis ST; Tasidou A; Terpos E; Dimopoulos MA
Am J Hematol; 2015 Apr; 90(4):E60-5. PubMed ID: 25580702
[TBL] [Abstract][Full Text] [Related]
12. Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis.
Cohen OC; Sharpley F; Gillmore JD; Lachmann HJ; Sachchithanantham S; Mahmood S; Fontana M; Whelan CJ; Martinez-Naharro A; Kyriakou C; Rabin N; Popat R; Yong K; Cheesman S; Shah R; Hawkins PN; Wechalekar AD
Br J Haematol; 2020 May; 189(4):643-649. PubMed ID: 31984481
[TBL] [Abstract][Full Text] [Related]
13. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.
Dispenzieri A; Dingli D; Kumar SK; Rajkumar SV; Lacy MQ; Hayman S; Buadi F; Zeldenrust S; Leung N; Detweiler-Short K; Lust JA; Russell SJ; Kyle RA; Gertz MA
Am J Hematol; 2010 Oct; 85(10):757-9. PubMed ID: 20872958
[TBL] [Abstract][Full Text] [Related]
14. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
15. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone.
Bochtler T; Hegenbart U; Kunz C; Benner A; Seckinger A; Dietrich S; Granzow M; Neben K; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
Amyloid; 2014 Mar; 21(1):9-17. PubMed ID: 24455967
[TBL] [Abstract][Full Text] [Related]
16. Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers.
Rezk T; Lachmann HJ; Fontana M; Naharro AM; Sachchithanantham S; Mahmood S; Petrie A; Whelan CJ; Pinney JH; Foard D; Lane T; Youngstein T; Wechalekar AD; Hawkins PN; Gillmore JD
Br J Haematol; 2019 Aug; 186(3):460-470. PubMed ID: 31124579
[TBL] [Abstract][Full Text] [Related]
17. Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.
Rezk T; Lachmann HJ; Fontana M; Sachchithanantham S; Mahmood S; Petrie A; Whelan CJ; Pinney JH; Foard D; Lane T; Youngstein T; Wechalekar AD; Bass P; Hawkins PN; Gillmore JD
Kidney Int; 2017 Dec; 92(6):1476-1483. PubMed ID: 28729034
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
[TBL] [Abstract][Full Text] [Related]
19. [Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
Charliński G; Wiater E; Jedrzejczak WW
Pol Merkur Lekarski; 2012 Apr; 32(190):217-20. PubMed ID: 22708276
[TBL] [Abstract][Full Text] [Related]
20. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.
Sidana S; Tandon N; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Kyle RA; Leung N; Go RS; Lust JA; Russell SJ; Zeldenrust SR; Rajkumar SV; Kumar SK
Leukemia; 2018 Mar; 32(3):729-735. PubMed ID: 28919633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
